Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.56 |
| ▸ | PPARG | P37231 | 12/20 | 0.56 |
| ▸ | PPARD | Q03181 | 9/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376825 | 0.90 | PPARA (0.68) | PPARAPPARGPPARDNR1H4 | |
| SCHEMBL377239 | 0.87 | PPARA (0.55) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL376645 | 0.87 | PPARA (0.54) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL377010 | 0.85 | PPARA (0.52) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL381707 | 0.84 | PPARA (0.51) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL381706 | 0.84 | PPARA (0.51) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL376998 | 0.79 | PPARG (0.65) | PPARAPPARGPPARDNR1H4 | |
| SCHEMBL376724 | 0.77 | PPARA (0.67) | PPARAPPARGPPARDNR1H4CYP2C9 | |
| SCHEMBL377166 | 0.76 | PPARA (0.66) | PPARAPPARGPPARD | |
| SCHEMBL2464845 | 0.74 | PPARA (0.57) | PPARAPPARGPPARDABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310494-B1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-6787552-B2 | HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040097739-A1 | Ppar delta activators | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1310494-A1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097739-A1 | Ppar delta activators | PPARD, PPARG, PPARA | PPARA 3/4885PPARG 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.